• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOMET FRANCE S.A.R.L. OPTIPAC 80 REFOBACIN PLUS BONE CEMENT-3; ORTHOPAEDIC CEMENT, MEDICATED

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOMET FRANCE S.A.R.L. OPTIPAC 80 REFOBACIN PLUS BONE CEMENT-3; ORTHOPAEDIC CEMENT, MEDICATED Back to Search Results
Catalog Number 4722502117-3
Device Problems Loose or Intermittent Connection (1371); Improper Chemical Reaction (2952)
Patient Problem Failure of Implant (1924)
Event Date 02/18/2021
Event Type  malfunction  
Manufacturer Narrative
Cmp-(b)(4).Natural tibia cemented 5 degree stemmed left size e, reference (b)(4), batch 64794770.Event occurred in (b)(6).The investigation is in progress.Once the investigation has been completed, a follow-up mdr will be submitted.If any further information is found which would change or alter any conclusions or information, a supplemental will be filed accordingly.
 
Event Description
It was reported that during left total knee arthroplasty following implant of the femoral component, in deep flexion position, the femur moved distally.Cement had not adhered to patients bone or femoral implant.Cement time was around 11-12 minutes, when femoral implant became loose and was removed.Surgeon assessed the knee and required to downsize femur to a size 7 left standard trabecular metal implant, which was a better fit.Ultra congruent poly and down sized femur to match the correct size for the tibia.There was a 60 minute delay in the procedure trouble shooting for new femur and re trialing implants.Patients posterior cruciate ligament was sacrificed and used ultra congruent poly instead of cruciate retaining.
 
Manufacturer Narrative
(b)(4).This follow-up report is being submitted to relay additional information.The following sections have been updated : b4, e1, e3, g3, g6, h2, h6, h10.An analysis of a product with the same reference and batch number has been realized.The product analysis shows that the product is an optipac and the cement is compliant with the specifications.The investigation is in progress.Once the investigation has been completed, a follow-up mdr will be submitted.If any further information is found which would change or alter any conclusions or information, a supplemental will be filed accordingly.
 
Event Description
It was reported that during left total knee arthroplasty following implant of the femoral component, in deep flexion position, the femur moved distally.Cement had not adhered to patients bone or femoral implant.Cement time was around 11-12 minutes, when femoral implant became loose and was removed.Surgeon assessed the knee and required to downsize femur to a size 7 left standard trabecular metal implant, which was a better fit.Ultra congruent poly and down sized femur to match the correct size for the tibia.There was a 60 minute delay in the procedure trouble shooting for new femur and re trialing implants.Patients posterior cruciate ligament was sacrificed and used ultra congruent poly instead of cruciate retaining.
 
Event Description
It was reported that during left total knee arthroplasty following implant of the femoral component, in deep flexion position, the femur moved distally.Cement had not adhered to patients bone or femoral implant.Cement time was around 11-12 minutes, when femoral implant became loose and was removed.Surgeon assessed the knee and required to downsize femur to a size 7 left standard trabecular metal implant, which was a better fit.Ultra congruent poly and down sized femur to match the correct size for the tibia.There was a 60 minute delay in the procedure trouble shooting for new femur and re trailing implants.Patients posterior cruciate ligament was sacrificed and used ultra congruent poly instead of cruciate retaining.
 
Manufacturer Narrative
This is a combination product: (b)(4).This follow-up report is being submitted to relay additional information.The product analysis can't be performed as the product was not returned.The device manufacturing quality record indicate that the released product met all requirements to perform as intended.No other complaint on patient death following medical: loosening/cement paste too long setting time was recorded on the batch since ever, and no other complaint on patient death following medical: loosening/cement paste too long setting time was recorded on the reference from (b)(6) 2018 to (b)(6) 2021.Reserve sample from the same lot was tested under standardized conditions.The product did not show any unusual behavior during mixing, handling or setting.According to available data, root cause of the event was unable to be determined.If any further information is found which would change or alter any conclusions or information, a supplemental will be filed accordingly.Zimmer biomet will continue to monitor for trends.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
OPTIPAC 80 REFOBACIN PLUS BONE CEMENT-3
Type of Device
ORTHOPAEDIC CEMENT, MEDICATED
Manufacturer (Section D)
BIOMET FRANCE S.A.R.L.
plateau de lautagne bp75
valence cedex 26903
FR  26903
MDR Report Key11485453
MDR Text Key266310454
Report Number3006946279-2021-00026
Device Sequence Number1
Product Code MBB
Combination Product (y/n)N
PMA/PMN Number
N/A
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup,Followup
Report Date 06/30/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date03/31/2021
Device Catalogue Number4722502117-3
Device Lot NumberC939A01408
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 02/18/2021
Initial Date FDA Received03/15/2021
Supplement Dates Manufacturer Received03/22/2021
06/30/2021
Supplement Dates FDA Received04/19/2021
06/30/2021
Is This a Reprocessed and Reused Single-Use Device? No
Removal/Correction NumberN/A
Patient Sequence Number1
Treatment
ASSOCIATED DEVICES LISTED IN H10.
Patient Outcome(s) Hospitalization; Required Intervention;
-
-